By NewsDesk @bactiman63
On Saturday, the Finnish Medicines Agency Fimea reported two cases of cerebral venous sinus thrombosis (clots in the vessels draining blood from the brain) within 4–10 days of receiving the AstraZeneca COVID-19 vaccine. Both patients had medical risk factors for blood clots, and the analysis of the cases is still incomplete.
As a precautionary measure, the Finnish Institute for Health and Welfare (THL) has decided to suspend the use of the AstraZeneca vaccine in Finland until more information on the cases is available and possible causality can be determined. The suspension is effective immediately.
The situation will be assessed during the coming week, and vaccinations with the AstraZeneca vaccine can continue at the earliest on March 29. THL will report on its findings without delay. Vaccinations with other vaccines will continue normally.
The National Advisory Committee on Vaccines (KRAR), appointed by THL, is in favour of limiting the use of the AstraZeneca vaccine as the analysis of the cases is incomplete.
In its report released on March 18, the European Medicines Agency (EMA) assesses that the benefits of the AstraZeneca COVID-19 vaccine continue to outweigh the risks of side effects.
- Leishmania: Dogs infected with the parasite smell more attractive to female sandflies
- Ukraine reports nearly 1400 HIV cases in February
- Chile tightens travel restrictions as record COVID-19 cases reported
- Germany resumes use of AstraZeneca vaccine as COVID-19 infections rise
- Parasites treatment: Ivermectin is safe and well tolerated in young children
- Norway will keep use of the AstraZeneca vaccine on hold as review continues
- 114 new COVID-19 cases in Philippines linked to new virus variants